Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 as an Optical Imaging Agent During Neurosurgery
NCT03510208Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- May 2018
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab in malignant glioma and vestibular schwannoma (VS) (4 cohorts), sponsored by Stanford University. Primary endpoint: Number of grade 2 or higher adverse events at 30 days. Started May 2018; status: recruiting.
02
Drugs
panitumumab
03
Conditions
malignant gliomavestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT03510208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510208.